Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

February 19, 2026HaematologicaOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to assess the effectiveness of ruxolitinib in pediatric patients with chronic graft-versus-host disease who are treatment-naive or corticosteroid-refractory.
Conducted a phase 2 trial known as REACH5.
Included pediatric patients who were either treatment-naive or refractory to corticosteroids.
Evaluated outcomes related to patient response to ruxolitinib treatment.
Demonstrated positive responses in managing chronic graft-versus-host disease.
Showed potential for ruxolitinib as a viable treatment option.
Indicated improved clinical outcomes compared to previous treatment approaches.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Phase 2 trial evaluates ruxolitinib's efficacy in pediatric patients with chronic graft-versus-host disease, indicating promising outcomes.

No takes yet. Share an insight, caveat, or question.

Locatelli et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share